Ipsen presents strong full-year 2022 results and guidance for 2023
Paris (France), 9 February 2023
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents today its financial results for the year and the fourth quarter of 2022.
Ipsen presents strong full-year 2022 results and guidance for 2023
Paris (France), 9 February 2023
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents today its financial results for the year and the fourth quarter of 2022.
Related Press Releases
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in...
Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic...
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal...
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL...
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL...
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL...